Lantern Pharma Inc. (LTRN) Insider Trading Activity

NASDAQ$1.905
Market Cap
$24.31M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
245 of 853
Rank in Industry
145 of 492

LTRN Insider Trading Activity

LTRN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$200,001
2
100
Sells
$0
0
0

Related Transactions

KEYSER D JEFFREYdirector
1
$100,001
0
$0
$100,001
Schalop Lee Troydirector
1
$100,001
0
$0
$100,001

About Lantern Pharma Inc.

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.

Insider Activity of Lantern Pharma Inc.

Over the last 12 months, insiders at Lantern Pharma Inc. have bought $200,001 and sold $0 worth of Lantern Pharma Inc. stock.

On average, over the past 5 years, insiders at Lantern Pharma Inc. have bought $200,001 and sold $1.83M worth of stock each year.

Highest buying activity among insiders over the last 12 months: KEYSER D JEFFREY (director) — $100,001. Schalop Lee Troy (director) — $100,001.

The last purchase of 48,544 shares for transaction amount of $100,001 was made by Schalop Lee Troy (director) on 2026‑05‑12.

List of Insider Buy and Sell Transactions, Lantern Pharma Inc.

2026-05-12PurchaseKEYSER D JEFFREYdirector
48,544
0.4294%
$2.06
$100,001
+49.51%
2026-05-12PurchaseSchalop Lee Troydirector
48,544
0.4294%
$2.06
$100,001
+49.51%
2025-06-13SaleKreis Leslie W.10 percent owner
40,000
0.3758%
$3.09
$123,600
+12.13%
2025-06-13SaleFletcher Aaron G.L.10 percent owner
40,000
0.3758%
$3.09
$123,600
+12.13%
2025-06-12SaleKreis Leslie W.10 percent owner
60,647
0.5885%
$3.38
$204,987
+5.88%
2025-06-12SaleFletcher Aaron G.L.10 percent owner
60,647
0.5885%
$3.38
$204,987
+5.88%
2025-06-11SaleKreis Leslie W.10 percent owner
950
0.0089%
$3.40
$3,230
+0.89%
2025-06-11SaleFletcher Aaron G.L.10 percent owner
950
0.0089%
$3.40
$3,230
+0.89%
2025-06-10SaleKreis Leslie W.10 percent owner
16
0.0001%
$3.40
$54
+1.19%
2025-06-10SaleFletcher Aaron G.L.10 percent owner
16
0.0001%
$3.40
$54
+1.19%
2025-05-29SaleKreis Leslie W.10 percent owner
20,200
0.1813%
$3.03
$61,206
+7.99%
2025-05-29SaleFletcher Aaron G.L.10 percent owner
20,200
0.1813%
$3.03
$61,206
+7.99%
2025-05-28SaleKreis Leslie W.10 percent owner
15,000
0.1391%
$2.87
$43,050
+17.42%
2025-05-28SaleFletcher Aaron G.L.10 percent owner
15,000
0.1391%
$2.87
$43,050
+17.42%
2025-05-27SaleKreis Leslie W.10 percent owner
21,037
0.2052%
$3.05
$64,163
+16.21%
2025-05-27SaleFletcher Aaron G.L.10 percent owner
21,037
0.2052%
$3.05
$64,163
+16.21%
2024-05-24SaleKreis Leslie W.10 percent owner
20,000
0.1889%
$6.33
$126,600
-39.08%
2024-05-24SaleFletcher Aaron G.L.10 percent owner
20,000
0.1889%
$6.33
$126,600
-39.08%
2024-05-23SaleKreis Leslie W.10 percent owner
10,000
0.0932%
$6.25
$62,500
-38.60%
2024-05-23SaleFletcher Aaron G.L.10 percent owner
10,000
0.0932%
$6.25
$62,500
-38.60%
Total: 35
*Gray background shows transactions not older than one year

Insider Historical Profitability

5.48%
KEYSER D JEFFREYdirector
94303
0.7391%
$179,647.2220
+5.48%
Schalop Lee Troydirector
48544
0.3805%
$92,476.3210
Fletcher Aaron G.L.10 percent owner
49957
0.3915%
$95,168.09015
Kreis Leslie W.10 percent owner
49957
0.3915%
$95,168.09015
BP Directors, LP
26093
0.2045%
$49,707.1701
BIOS Advisors GP, LLC
26093
0.2045%
$49,707.1701
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$6,204,522
45
1.91%
$28.45M
$30,257,839
29
-15.72%
$23.91M
$241,165
22
-16.72%
$32.32M
$555,628
21
43.52%
$20.2M
$114,619,342
20
-7.41%
$19.67M
$352,389
18
9.66%
$33.23M
$20,234,041
17
2.09%
$40.57M
$1,246,170
12
65.67%
$20.72M
$176,752
10
-28.86%
$23.38M
$4,176,565
9
18.77%
$22.6M
$8,971,546
8
6.18%
$19.9M
$654,995
7
-60.00%
$20.68M
$114,586
6
-12.52%
$25.14M
$26,254,149
5
49.97%
$38.43M
$5,306,958
5
11.70%
$36.3M
$1,499,988
3
0.92%
$35.41M
$35,811
1
-10.94%
$23.7M
Lantern Pharma Inc.
(LTRN)
$150,000
1
5.48%
$24.31M
$5,512,500
1
-7.91%
$28.25M

LTRN Institutional Investors: Active Positions

Increased Positions12+31.58%95,973+4.22%
Decreased Positions13-34.21%92,488-4.06%
New Positions6New78,606New
Sold Out Positions4Sold Out38,774Sold Out
Total Postitions37-2.63%2M+0.15%

LTRN Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Bios Capital Management, Lp$3,159.009.23%1.02M-60,237-5.6%2025-09-30
Vanguard Group Inc$1,194.003.49%384,041+20,321+5.59%2025-09-30
Cm Management, Llc$700.002.05%225,000+25,000+12.5%2025-09-30
Renaissance Technologies Llc$311.000.91%100,100+9,500+10.49%2025-09-30
Geode Capital Management, Llc$286.000.84%92,081+190+0.21%2025-09-30
Voss Capital, Lp$156.000.46%50,00000%2025-09-30
Newedge Advisors, Llc$147.000.43%47,279-9,228-16.33%2025-09-30
Blackrock, Inc.$134.000.39%43,090+815+1.93%2025-09-30
Dimensional Fund Advisors Lp$125.000.37%40,144-796-1.94%2025-09-30
Susquehanna International Group, Llp$122.000.36%39,094+39,094New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.